Announcement on progress of share repurchase
Securities code: 688606 Securities abbreviation: Aotai Biotechnology Announcement number: 2026-015
Hangzhou Aotai Biotechnology Co., Ltd.
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The first disclosure date of the repurchase plan is 2026/1/22
The implementation period of the buyback plan is from February 9, 2026 to February 8, 2027
The estimated repurchase amount is 100 million yuan to 200 million yuan
√Reduce registered capital
□For employee stock ownership plans or equity incentives
Repurchase purpose
□Used to convert company convertible bonds
□To protect the company’s value and shareholders’ rights and interests
The cumulative number of shares repurchased is 1,129,610 shares
The cumulative number of repurchased shares accounts for 1.42% of the total share capital.
The cumulative repurchased amount is 74,432,660.41 yuan
Actual repurchase price range: 62.62 yuan/share ~ 68.29 yuan/share
1. Basic information on share repurchase
Hangzhou Aotai Biotechnology Co., Ltd. (hereinafter referred to as the "Company") on January 21, 2026, On February 6, 2026, the 19th meeting of the third board of directors and the first extraordinary shareholders' meeting of 2026 were held respectively, and the "Proposal on the Plan for Repurchasing the Company's Shares through Centralized Bidding Transactions" was reviewed and approved, and it was agreed that the company would use the excess funds raised from the initial public offering of stocks to conduct centralized bidding transactions through the Shanghai Stock Exchange trading system. The repurchased shares will be all used for cancellation or reduction of registered capital. The repurchase price shall not exceed RMB 85 per share (inclusive). The total repurchase funds shall not be less than RMB 100 million (inclusive) and shall not exceed RMB 200 million (inclusive). The repurchase period shall commence from the date when the company's shareholders meeting approves the repurchase plan. Within 12 months. For details, please refer to the "Repurchase Report on the Repurchase of Shares through Centralized Bidding Transactions" (Announcement Number: 2026-011) disclosed by the company on the Shanghai Stock Exchange website (http://www.sse.com.cn) on February 7, 2026.
2. Progress of share repurchase
In accordance with the "Share Repurchase Rules of Listed Companies", "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, the progress of the company's share repurchase is now announced as follows:
As of March 23, 2026, the company has repurchased a total of 1,129,610 shares of the company through centralized bidding transactions, accounting for 79,280,855 shares of the company's total share capital. 1.42%, the highest price of the repurchase transaction was 68.29 yuan/share, the lowest price was 62.62 yuan/share, and the total amount of funds paid was RMB 74,432,660.41 (excluding stamp duty, transaction commission and other transaction fees).
This share repurchase complies with the provisions of laws and regulations and the company's share repurchase plan.
3. Other matters
The company will strictly abide by the "Share Repurchase Rules for Listed Companies", "Shanghai Stock Exchange Self-Regulatory Supervision Guidelines for Listed Companies No. 7 - Repurchase of Shares" and other relevant regulations, make repurchase decisions based on market conditions during the repurchase period and implement them. At the same time, it will perform information disclosure obligations in a timely manner based on the progress of the share repurchase matter. Investors are advised to pay attention to investment risks.
Announcement is hereby made.
Board of Directors of Hangzhou Aotai Biotechnology Co., Ltd.
March 24, 2026